This page collects WhisperX intelligence signals tagged #Drug Discovery. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
Eli Lilly is aggressively expanding its AI-powered drug discovery pipeline, committing billions of dollars in a new strategic collaboration with Hong Kong-based biotech firm Insilico Medicine. This move signals a major escalation in the pharmaceutical industry's race to harness artificial intelligence for faster, more ...
AI drug developer Insilico Medicine has secured a major commercialization deal with pharmaceutical giant Eli Lilly, a pact valued at up to $2.75 billion. The agreement, announced Sunday, grants Lilly the rights to develop, manufacture, and commercialize a portfolio of Insilico's preclinical drug candidates discovered u...
Novo Nordisk is making a decisive move into the future of pharmaceutical R&D by forging a strategic partnership with OpenAI. This collaboration aims to significantly boost the company's drug discovery efforts by leveraging advanced artificial intelligence. The alliance signals a major commitment from the Danish pharmac...
OpenAI has launched its first domain-specific artificial intelligence model, but its capabilities are locked behind a wall of exclusivity. Named GPT-Rosalind, the system is engineered specifically for the high-stakes fields of drug discovery and life sciences, representing a targeted move beyond the company's general-p...